Preliminary evidence suggests that fenoldopam mesylate, a selective
dopamine-1 receptor agonist, preserves renal blood flow after iodinated contrast
administration, potentially reducing risk of contrast-induced nephropathy.
In this randomized trial, however, Stone and colleagues found that risk of
contrast-induced nephropathy was not significantly different among patients
with chronic renal insufficiency undergoing invasive cardiac procedures who
received fenoldopam mesylate compared with those who received placebo.